Antibiotic resistance among clinically important gram-positive bacteria in the UK

J Hosp Infect. 1998 Sep;40(1):17-26. doi: 10.1016/s0195-6701(98)90020-2.


The resistance of bacteria to antibiotics, particularly those used for first-line therapy, is an increasing cause for concern. In the UK, the prevalence of resistance to methicillin and mupirocin in Staphylococcus aureus, and to penicillin and macrolides in Streptococcus pneumoniae, appear to be increasing. There has also been an increase in the number of hospitals where glycopeptide-resistant enterococci are known to have been isolated. The increases in methicillin-resistant S. aureus and glycopeptide-resistant enterococci are due, in part, to the inter-hospital spread of epidemic strains. Although new quinolones and streptogramins with activity against Gram-positive bacteria (including strains resistant to currently available agents) are under development, there is no reason to believe that resistance to these agents will not emerge. The control of resistance in Gram-positive bacteria will require a multi-faceted approach, including continued and improved surveillance, a reduction in the unnecessary use of antibiotics, and the application of other strategies such as vaccination.

Publication types

  • Review

MeSH terms

  • Drug Resistance, Microbial*
  • Enterococcus / drug effects
  • Gram-Positive Bacteria / drug effects*
  • Gram-Positive Bacterial Infections / drug therapy*
  • Humans
  • Pneumococcal Infections / drug therapy
  • Staphylococcal Infections / drug therapy
  • Staphylococcus aureus / drug effects
  • Streptococcus pneumoniae / drug effects
  • United Kingdom